introduc new model updat thought maintain perform
initi coverag perform rate valuat
initi outperformdisplay valu
color fundament focu call
runway extend anticip phase readout
leukemia lymphoma updat come june
manag meet take-away specif reason sell-off
analyst certif import disclosur see
ceo sloan step resolut start
gilead report registr phase result two studi rheumatoid arthriti ra plu anoth long-term phase dataset
point previous finch readout late filgotinib look increasingli like best-in-class due
dose-rel benefit/risk profil see exhibit full report releas today minim impact venou thromboembol event
vte major adjud cardiac event mace safeti concern bedevil class drug limit uptak
two approv baricitinib tofacitinib physician check indic filgotinib emerg profil valu
ra indic stay bullish
host investor meet ever cfo ir manag tone improv traffic trend consist earn
call public commentari recent investor confer takeaway favor industri tailwind benefit top line creat
direct integr provid limit chang competit dynam provid opportun multipl player
succeed guidanc impli balanc growth pricing/volum target break-even ebitda back-half follow
meet encourag traffic stabil octob see lead consist execut
indic gain increment share carrier advertis budget potenti lead upward estim revis reiter outperform
price target
yesterday manag gave upbeat set present annual investor day san francisco found manag
updat construct manufactur opportun product portfolio go-to-market strategi growth driver free
cash flow gener beyond integr recent acquisit posit bottom line see autodesk well posit
portfolio applic technolog vision referenc gain share larg design make tam believ
multipl lever busi pull drive next leg growth compound-annual-growth-rate target gener
compound-annual-growth-rate target subscript transit mostli complet support valuat reiter outperform
introduc new model updat thought maintain perform
reconstruct model avail upon request align compani recent reorgan new oper segment
also updat earn analysi management continu solidli execut plan remodel us asset specif relat
consensu ep work point lack upsid owe margin pressur better compstore trend alreadi underwritten
consensu expect flat-to-low singl ep growth mid-to-high singl high-singl
normal cost environ ep grow high-single-digit compstore street assum healthi top-lin uniqu
cost headwind restrict earn model potenti spillov price-to-earnings maintain perform rate
initi coverag perform rate valuat
initi coverag perform rate valuat struggl justifi premium valuat sale vs peer
sale compound-annual-growth-rate compar peer oper global creativ commerc platform connect buyer
seller compani provid tool manage/scal small busi buyer search brows buy
item know transact secur guarante sinc may josh silverman took ceo upgrad
team turn around busi base market share analysi believ four dynam support growth beyond
ship price cloud transit leverag market brand awar
initi outperformdisplay valu
lead player secularli grow out-of-hom ooh advertis industri repres uniqu invest opportun
compani recent restor growth success renew contract mta boast numer growth opportun includ small
 digit mobil cell site leas also believ compani could consolid target fifth anniversari reit
convers pass juli deal becom significantli tax-friendli initi coverag outperform
rate price target
color fundament focu call
runway extend anticip phase readout
thursday biolinerx report earn review recent progress earli result lead-in cohort genesi studi dmc
clearanc advanc random portion trial bolster confid posit readout expect see
interim analysi on-going blast trial remind blast explor whether ad consolid chemotherapi
improv relapse-fre surviv patient aml separ could see updat studi combin atezolizumab
first-in-human result triplet combin data pancreat cancer recent financ bring compani pro forma
cash posit could sustain oper beyond top-lin genesi result reiter outperform pt
leukemia lymphoma updat come june
thursday forti seven announc result quarterli call manag reiter plan present updat phase result
nhl medic confer expect signific updat includ initi efficaci data dose expans patient along
extend follow-up patient earlier cohort impress cr rate maintain patient updat believ
could strong candid breakthrough therapi design addit expect see initi data combin azacitidin
aml updat on-going trial ovarian colorect cancer slate buyer ftsv ahead key
manag meet take-away specif reason sell-off expect import dfu updat april
yesterday met discuss compani outlook prior present data skint diabet limb salvag confer
dl april discuss recent weak share price manag confirm chang fundament busi
expect awar reason recent weak share expect data around ten diabet foot ulcer
dfu patient dl meet repres largest dataset dfu patient present date look percentag patient
achiev full wound closur three week primari efficaci metric believ need access equiti market near term
top stori announc acquir wcg cash stock shrs/wcg deal total
overal believ deal right strategi give signific diversif much larger medicar presenc reason
price deal put new tier signific player among diversifi mco solidifi growth path year
manag meet see link report page
cloud expand ai portfolio
challeng server processor market domin digitim
dram market shrink substanti digitim
globalwaf suppli wafer remain tight digitim
last night market close outperform-r report final jan result outlin initi guidanc fiscal
jan share trade higher throughout day end caught senior manag short ago
takeaway discuss difficult quantifi out-performance toy categori jan help drive increment
pt comp initi guidanc like introduc new custom store much like spinner craze
throughout softer margin holiday quarter occur larg result last-minut inventori acquisit toy game
trend expect normal cours work strateg key vendor plan roll-out new
merchandis shift holiday later apr like push sale toward back half apr
still yield comp rang compani multi-year store remodel program underway manag expect
mid-singl digit comp lift revamp unit first full year oper new store product continu track extrem well
jan adjust week prior year time shift recent launch coverag
earli report entitl one remain retail growth stori note remind client posit stanc
share intermedi longer term natur
ir total ytd ir releas eighth tax return file data updat compar friday vs friday
ytd total ir return received/tot ir e-fil receipt declin y/i respect despit tax season slow start still
anticip low-singl digit ir volum growth y/i season-end
ir channel ytd vs comparison period ir e-fil receipt tax profession declin y/
self-prepar e-fil receipt increas y/i
channel spread ytd spread y/i profession prepar e-fil receipt declin y/i self-prepar e-fil receipt
increas minu vs y/i wider compar period y/i spread ir report
spread narrow compar spread vs compar time period
histor profession vs self-prepar spread narrow progress tax season
end season spread favor self-prepar tax file trend appear similar past
turbotax block ytd activ mid-februari turbotax volum growth pace line ir self-prepar
e-fil receipt february-end block do-it-yourself volum growth pace well ahead ir self-prepar e-fil
earli march turbotax transit late season mean increas price on-line premier offer free
edit remain free last year turbotax discontinu free edit mid-march
mid-march block transit late season price on-line premium offer flat y/i vs earli
season strategi price lower y/i block free on-line offer current remain free last year block discontinu free
march-end
sustain growth resourc optim
announc reduct lithium volum lower guidanc quarter reaffirm guidanc compani
point delay qualif materi xinyu ii facil understand fulli qualifi custom well water
access problem la negra public water infrastructur stress due higher normal precipit expect investor
mix reaction believ short case lithium around excess product lack demand howev announc point
challeng product well meet batteri spec believ allevi qualif issu manag
water access issu chile would buyer weak
jefferi issu first full quarter integr result invest bank merchant bank result present
togeth alway mainli earn releas jefferi llc broker-deal side hous result
sharpli lower expect essenti attribut near stop underwrit activ trade
part hous seem fine bake declin underwrit revenu came
manag cite decemb market stress govern shut key factor recov given
ceo sloan step resolut start process
well announc close ceo tim sloan retir compani effect relinquish ceo role immedi
gener counsel allen parker serv interim ceo extern search begun perman ceo stock react
favor aftermarket may well import step recoveri rehabilit process would caution
view stuff great intermediate-term say month stock perform made
june summit emerg biotechnolog montauk ny
